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Type 1 diabetes (T1D) is the most common paediatric endocrine disease, and its
frequency has been found to increase worldwide. Similar to all conditions associated
with poorly regulated glucose metabolism, T1D carries an increased risk of infection.
Consequently, careful compliance by T1D children with schedules officially approved for
child immunization is strongly recommended. However, because patients with T1D show
persistent and profound limitations in immune function, vaccines may evoke a less efficient
immune response, with corresponding lower protection. Moreover, T1D is an
autoimmune condition that develops in genetically susceptible individuals and some
data regarding T1D triggering factors appear to indicate that infections, mainly those
due to viruses, play a major role. Accordingly, the use of viral live attenuated vaccines is
being debated. In this narrative review, we discussed the most effective and safe use of
vaccines in patients at risk of or with overt T1D. Literature analysis showed that several
problems related to the use of vaccines in children with T1D have not been completely
resolved. There are few studies regarding the immunogenicity and efficacy of vaccines in
T1D children, and the need for different immunization schedules has not been precisely
established. Fortunately, the previous presumed relationship between vaccine
administration and T1D appears to have been debunked, though some doubts
regarding rotavirus vaccines remain. Further studies are needed to completely resolve
the problems related to vaccine administration in T1D patients. In the meantime, the use of
vaccines remains extensively recommended in children with this disease.
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The anti-infective vaccines included in the immunization schedule adopted by most countries for
protecting children can cause several problems when these prophylactic measures have to be given
to subjects at risk of or with overt type 1 diabetes (T1D). T1D is the most common paediatric
endocrine disease, and its frequency has been found to increase worldwide with relevant medical,
social and economic issues (1). According to the International Diabetes Federation, it was estimated
that more than 1.1 million children and adolescents around the world were living with T1D in 2019
compared to 860,000 in 2013 (2). Similar to all conditions associated with poorly regulated glucoseorg August 2021 | Volume 12 | Article 6678891
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diabetes (T2D), T1D carries an increased risk of infection.
Consequently, careful compliance by T1D children with
schedules officially approved for child immunization by
national governments is strongly recommended by scientific
societies (3).
A list of vaccines for the prevention of the most common
infectious diseases diagnosed in adults with T1D and T2D is
recommended for children with T1D (4). However, because
patients with T1D show persistent and profound limitations in
immune function (5, 6), vaccines may evoke a less efficient
immune response, with corresponding lower protection. A
larger use of boosters to maintain elevated protection has been
suggested for some vaccines (3). Moreover, T1D is an
autoimmune condition (7–11) that develops in genetically
susceptible individuals (12), when epigenetic or environmental
factors act as triggers and modulate the penetrance of
susceptibility genes (13). For example, associations of T1D
development with some nutrients such as cow’s milk and
gluten as well as increased maternal age and rate of postnatal
growth, vitamin D deficiency, chemical exposure, and gut
dysbiosis have been suggested (14–18). Nevertheless, most data
regarding T1D triggering factors appear to indicate that
infections, mainly those due to viruses, play a major role.
Enteroviruses and herpesviruses have frequently been
associated with T1D development, but other viruses, including
some of those used to prepare vaccines such as rotavirus,
influenza viruses, rubella and mumps viruses, have also been
found to cause pancreatic infection and autoimmunity (19).
Accordingly, the use of vaccines is being debated, as this
hypothesis is reinforced by some epidemiological evidence
(20–22). In this narrative review, these issues are discussed to
define the most effective and safe use of vaccines in patients at
risk of or with overt T1D.INFECTIONS IN TYPE 1
DIABETES PATIENTS
Risk of Infection
Together with multisystem microangiopathy and macrovascular
disease (23), immune compromise is the most common
complication of poor glycaemic control. The immune response
is disrupted in any type of diabetes, and both the innate and
adaptive immune systems are impaired. Defects in pathogen
recognition, suppression of cytokine production, poor neutrophil
and macrophage recruitment and function, alteration in natural
killer cell activity, and inhibition of antibodies and complement
effectors have been repeatedly reported in both experimental
animals and humans with T1D and T2D (24). Indeed, despite a
few exceptions (25, 26), studies involving adults have clearly
shown that patients with T1D are at increased risk of infection
(27–29). In a 12-month prospective cohort study carried out in
the Netherlands from May 2000 through April 2002, it was
demonstrated that the incidence of lower respiratory tract
infections was significantly higher among 705 T1D patientsFrontiers in Immunology | www.frontiersin.org 2than among 18,911 controls (adjusted odds ratio [AOR], 1.42;
95% confidence interval [CI] 0.96–2.08), with urinary tract
infection (AOR, 1.96 [95% CI 1.49–2.58]), bacterial skin and
mucous membrane infections (AOR, 1.59; 95% CI 1.12–2.24)
and mycotic skin and mucous membrane infection (AOR, 1.34;
95% CI 0.97–1.84) being common (30).
Furthermore, risk increased with recurrence. These findings
were confirmed by a more recent study performed using English
primary care data collected during 2010-2015 in which the
incidence and outcome of infections were related to the degree
of T1D severity measured through HbA1c evaluation (31). In
this study, 5,863 T1D patients were matched with 8,231 controls,
and patients requiring a prescription or hospitalization or who
died were compared. The results showed that long-term
infection risk rose with increasing HbA1c for most outcomes.
Hospitalization for infection was significantly more frequent in
patients with T1D than in controls (incidence rate ratio [IRR]
3.34; 95% CI 2.82–3.96), and poor glycaemic control was
associated with an increased risk: subjects with HbA1c ≥11%
had an IRR of 8.47 (95% CI 5.86-12.24), whereas those with
optimal control had an IRR of 1.41 (95% CI 1.36–1.47). The
largest relative associations between the poorest level of
glycaemic control and optimal control were seen for bone and
joint infections, endocarditis, and sepsis. In addition, a strict
relationship between poor glycaemic control and infection
severity has been recently shown in severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)-infected patients. T2D
was found to be among the most common medical condition in
adult patients developing COVID-19 (32), and it was associated
with an almost fourfold greater risk for severe disease and death
(OR 3.68, 95% CI 2.68–5.03; P < 0.001) (33).
Unfortunately, the incidence of infections in T1D paediatric
patients has been poorly studied. Most of the available evidence
comes from studies conducted in adults and the evidence
suggesting a higher risk of infections in children with T1D is
extremely weak. On the other hand, it is common experience of
clinicians looking after these patients that they do not show any
increased risk of infections, especially severe infections.
Nonetheless, as children with poor glycaemic control have
immune and metabolic disorders similar to those found in
adults, it seems likely that children may have a risk of infection
substantially similar to that in adults. Support for this hypothesis
can be found in a retrospective study in the USA using data
collected from 2008 to 2014 at 44 freestanding children’s
hospitals across the country (34). The authors analysed the
clinical characteristics of children and adolescents with T1D
who presented to the emergency department (ED) or were
hospitalized for infection management. A total of 104,739 cases
were studied: 34,332 visited the ED, and 60,407 visited the
hospital. The data showed that medical attention for infections
is routinely given to paediatric patients with T1D and that the
need for assistance for these patients increases over time in
parallel with the increase in T1D cases, with a relevant impact on
assistance costs that increased from $189 to $218 million dollars
per year. Considering COVID-19, overall, the accumulating
evidence suggests that children with T1D infected with severeAugust 2021 | Volume 12 | Article 667889
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similar disease outcomes as peers without diabetes (35, 36).
Type of Infections in Patients With Type 1
Diabetes (T1D)
As previously highlighted, some infections are common in T1D
patients. Respiratory infections caused by Mycobacterium
tuberculosis, Staphylococcus aureus, gram-negative bacteria and
fungi may occur with an increased frequency (37, 38). Infections
due to Streptococcus pneumoniae (39) and influenza viruses
deserve particular attention because they are extremely more
common than in healthy subjects and are associated with a
significantly increased risk of hospitalization and death (40, 41).
Skin and soft tissue infections ranging from folliculitis,
furunculosis, and subcutaneous abscesses to necrotizing
fasciitis are frequently caused by methicillin‐resistant S. aureus
and Staphylococcus epidermidis (42). Urinary tract infections are
described in diabetic subjects up to 10 times more frequently
than in healthy subjects. Moreover, these infections are 4 times
more commonly associated with bacteraemia than in healthy
subjects and are frequently due to multi‐drug‐resistant microbes
(43). Among gastrointestinal diseases, hepatitis B (HB) (44),
hepatitis C (45) and oral and oesophageal candidiasis (46) are
common in those with T1D.IMMUNE RESPONSE AND CLINICAL
EFFICACY OF RECOMMENDED
VACCINES IN PATIENTS WITH
TYPE 1 DIABETES (T1D)
Children and adolescents with T1D are considered a special
population requiring vaccination according to the immunization
schedule recommended for healthy subjects, with particular
attention to pneumococcal and influenza vaccines. Boosters of
pneumococcal vaccines may be necessary, and influenza vaccines
must be rigorously administered each year (3). In adults with
T1D, there are specific recommendations for the administration
of the hepatitis B (HB) vaccine, tetanus/diphtheria/acellular
pertussis vaccine, pneumococcal vaccine, influenza vaccine and
herpes zoster vaccine according to age and previous
immunizations (4).
However, despite the well-known impairment of immune
system function in T1D patients, the immune response to
commonly recommended vaccines in these subjects has been
poorly studied. Moreover, the results of the few available studies
are conflicting and do not allow us to draw definitive conclusions
regarding the real protection offered by the different vaccines in a
single T1D patient. Evaluation of the immune response of 20
T1D patients to hepatitis A (HA), diphtheria and pneumococcal
polysaccharide vaccines showed that T1D patients had a
significantly impaired primary antibody response to HA
vaccine (P = 0.017) and diphtheria toxoid (P = 0.004)
compared to healthy controls but that the response to
pneumococcal polysaccharide was normal (47). In anotherFrontiers in Immunology | www.frontiersin.org 3study enrolling 36 children with T1D and a similar number of
age-matched healthy controls in which the immune response to
conjugate pneumococcal vaccine, Hib vaccine and tetanus/
diphtheria vaccine was compared, no difference in antibody
levels against the antigens tested was found between the
groups. However, after a booster dose, the median level against
pneumococcal serotypes was significantly lower in the T1D
patients than in the controls (2.3 g/mL [range, 0.05 to
664.7 g/mL] and 6.1 g/mL [0.12 to 203.36 g/mL]), respectively,
suggesting reduced immune memory in the former (48).
Regarding the immune response to the HB vaccine, studies
carried out approximately 20 years ago showed that both the
immediate and long-term immune responses to the HB vaccine
in T1D patients did not differ from those of healthy subjects (49–
54). Paradigmatic in this regard are the studies of Marseglia et al.,
who monitored HBsAb titres immediately after the usual
schedule of immunization (0, 1 and 6 months) as well as 4
years later in T1D children/young adults and healthy subjects
(4.5 to 27.5 years of age). In both cases, the immune response was
similar in the T1D patients and controls. A few weeks after the
booster dose (49), 3 (4.6%) of 65 T1D patients and 3 (1.7%) of
174 age- and sex-matched healthy subjects were considered to
have a low (HBsAb titre = 10 IU/L) or no (HBsAb titre, < 2 IU/L)
response. Moreover, the median HBsAb titre was similar in the
responding patients (120 IU/L) and controls (125 IU/L). There
were no significant correlations between antibody titre and age,
diabetes duration, or HbA1c or insulin requirement. After 4
years, mean anti-HBs log-titres were 1.95 ± 0.88 in T1D patients
and 2.18 ± 0.64 in controls (P=0.11). Additionally, the number of
subjects with protective antibody concentrations (anti-HBs >10
IU/l) was 50/54 (92%) among T1D patients and 67/70 (96%)
among controls (P=0.70) (50). More recent studies have shown
the opposite. Leonardi et al. reported significantly more common
detection of protective serum anti-HBs antibody levels in
previously immunized children among healthy subjects (84%)
than patients with diabetes (58.2%) (P < 0.0001), regardless of
age or duration and metabolic control of T1D. Moreover, among
children with antibodies, the T1D children had significantly
lower antibody values (58 ± 112.9 mIU/mL vs 266.49 ± 335.85
mIU/mL, respectively; P < 0.0001) (55). Similar results were
reported by Elrashidy et al., who found protective anti-HBs levels
in only 30.2% of children with the disease compared to 60% of
healthy controls (P < 0.001), which was independent of the age of
patients and the duration of T1D (56). Finally, by analysing the
serological response to HBV vaccine in 69 T1D patients and 79
healthy controls who had received the third dose 6.8 and 4.7
years prior, Zanoni et al. (57) showed that although the total
number of subjects with protective antibody levels was quite
similar in both groups (72% vs 77%, respectively), mean serum
anti HBs antibody concentrations were lower in the patients than
in the controls (75 ± 149 mIU/mL vs 169 ± 268 mUI/mL,
respectively; P = 0.0068).
Dissimilar results were also reported when the influenza
vaccine was evaluated. A study enrolling 105 T1D subjects
aged 9-30 years who were randomized to receive either a
virosomal or a standard subunit influenza vaccine showed thatAugust 2021 | Volume 12 | Article 667889
Esposito et al. Vaccines in Type 1 Diabetesserum haemagglutinin inhibition antibody titres against the
three viruses included in the vaccines at one month post
vaccination met the requirements for immunogenicity, with
high seroprotection rates (>95%) for strains A/H1N1 and A/
H3N2 and seroprotection of 73% and 70% for the virosomal and
subunit vaccine for strain B, respectively (58). Similar results
were obtained by the same authors in a further study in which
T1D paediatric patients who received an influenza MF59-
adjuvanted vaccine were evaluated (59). However, in a previous
study, it was found that the incidence of non-response to the
H3N2 and influenza B components of a trivalent vaccine was
substantially lower in T1D patients than in healthy controls (100%
vs 78% and 80 vs 44%, respectively, p<0.05). Moreover, the
delayed-type hypersensitivity reaction to influenza antigen was
significantly decreased in patients with worse glycaemic control
(P < 0.01) (60).
Overall, the real efficacy of immunization in T1D patients has
not been established. As most T1D paediatric patients receive the
recommended vaccines at the proper time, the effect of no
vaccination cannot be easily evaluated. In fact, in a systematic
review and meta-analysis of the effectiveness of influenza
vaccines in patients with diabetes published in 2015 (61), no
data for children with T1D could be analysed because relevant
studies were unavailable. Furthermore, studies carried out in
adults generally consider patients with T1D and T2D together,
and the importance of T1D in conditioning the efficacy of
vaccines has not been evaluated. Regardless, the previously
cited systematic review and meta-analysis indicates that most
studies to date have a very low quality that makes it impossible to
determine to what extent vaccines are effective, even though they
suggest some beneficial effects of influenza immunization for
patients with diabetes.RISK OF TYPE 1 DEVELOPMENT AFTER
ADMINISTRATION OF VACCINES
A number of experimental and clinical observations have
suggested a potential relationship between infection and T1D
development. In experimental animals, viral infections,
particularly those due to coxsackieviruses, may cause
pancreatic infections and lead to T1D development. In
humans, the association between recurrent respiratory tract
infections in the first semester of life and the development of
pancreatic islet autoimmunity with overt T1D at approximately 8
years of age have been reported (62, 63). Enterovirus (EV)
epidemics have also been associated with an increased
incidence of T1D. For instance, evidence of infection and
detection of EV in the blood and stool were several times more
common in children with T1D than in controls (64–67). Similar,
although less stringent, results have been obtained for Epstein-
Barr virus (68, 69). Among viruses included in vaccines,
influenza (70), rubella (71), mumps (72) and rotavirus (73)
were initially considered potential triggers of T1D, though the
results of recent studies seem to exclude this risk for influenza
(74) as well as mumps and rubella (75). Doubt remains withFrontiers in Immunology | www.frontiersin.org 4regard to rotavirus, though a higher incidence of T1D among
children with clear evidence of a previous rotavirus infection has
been reported (76).
Four mechanisms have been proposed to explain how viruses
lead to autoimmunity: molecular mimicry, in which virus
proteins bearing similar sequences to pancreatic beta cell
components activate autoreactive T cells (77); bystander
activation, in which beta-cell proteins released during viral
infection are captured by antigen-presenting cells that present
host epitopes and activate immune response (78); epitope
spreading, in which immune responses to endogenous epitopes
secondary to the release of self-antigens during viral induced
chronic inflammatory pancreatic disease are the basis of
autoimmunity (79); and cryptic antigens, in which cryptic self-
determinants are presented to T cells in amounts sufficient to
induce autoimmunity (80). For molecular mimicry, this
hypothesis has been substantiated by several clear lines of
evidence. As an example, potential cross-reactivity between
structural components of coxsackievirus and human
cytomegalovirus and a pancreatic beta-cell component has
been reported (81, 82) as well as between the VP1 protein of
enterovirus and the beta-cell antigen tyrosine phosphatase IA-2
(83). There are also similarities between islet antigen-2 (IA-2), an
autoantigen associated with T1D, and the VP7 protein of a
human G3P rotavirus strain. Moreover, cross-reactivity of T cells
generated against rotavirus VP7 peptide with IA-2, and vice
versa, has been reported (84).
The hypothesis that vaccines might have the same potential
role already reported for some viruses and trigger T1D
development was initially strongly substantiated by a number
of studies. In most cases, the temporal association between
vaccine introduction in the immunization schedule of infants
and children and the sudden increase in T1D incidence in the
same paediatric population was considered key for
demonstrating that vaccines might cause T1D. For example,
clustering of T1D cases at approximately 2-4 years after
Haemophilus influenzae type B (Hib) vaccine, pertussis
vaccine, combined measles, mumps, rubella (MMR) vaccine,
and BCG vaccine administration has been reported (85). As
the time distance between the onset of autoantibodies against
pancreatic beta cells and the development of overt T1D is
generally the same, this was considered strong evidence of the
risk related to vaccine use. A relationship between vaccine and
T1D development and the time of the first vaccine
administration was proposed. Certain vaccines, such as the HB
vaccine and BCG vaccine, might decrease the risk of developing
T1D if given at birth; first vaccination at 2 months of life or later
might also increase the risk (86). However, most experts did not
attribute significant importance to these findings, and
recommendations for infant and child immunization were not
modified. The results of these studies were debated mainly
because most of them had significant methodological
limitations, enrolling a small number of unvaccinated subjects
or being statistically underpowered. Moreover, these reports
were counterbalanced by a large number of studies showing
that vaccines were safe and not associated with an increased riskAugust 2021 | Volume 12 | Article 667889
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the vaccines had been found to be associated with this disease. A
protective effect was even evidenced in some studies (75). The
findings of these studies can be illustrated by some examples. In a
case-control study carried out in Sweden that included 339 cases
and 528 controls (87), BCG, smallpox, pertussis, tetanus, rubella,
and mumps vaccines had no influence on T1D epidemiology,
whereas measles vaccine was associated with protection from
T1D development (OR = 0.69; 95% CI 0.48-0.98). In a
retrospective study carried out in Canada in which BCG
vaccination was evaluated, a trend in favour of a protective
effect of the vaccine was found, even though the small number of
children receiving the BCG vaccine did not allow for drawing
firm conclusions (88). Among children vaccinated at birth, only
one (3.3%) was diagnosed with T1D by the age of 5 years,
compared with 52 (24.5%) who had not been vaccinated
(P < 0.01) (88). A 10-year follow-up study carried out in
Finland, where a relationship between Hib vaccine and T1D
development had been speculated a few years after introduction
of the vaccine (83), did not implicate this vaccine regard and
showed no significant difference in risk between children
vaccinated against Hib at the age of 3 months and at the age of
24 months (89). A large, population-based, case-control study
carried out in the USA reported that none of the evaluated
vaccines was associated with an increased risk of T1D. The OR
for the association with T1D was 0.28 (95% CI 0.07–1.06) for the
whole cell pertussis vaccine, 1.36 (95% CI 0.70–2.63) for MMR,
1.14 (95% CI 0.51–2.57) for Hib, 0.81 (95% CI 0.52–1.27) for the
HB vaccine, 1.16 (95% CI 0.72–1.89) for the varicella vaccine,
and 0.92 (95% CI 0.53–1.57) for acellular pertussis-containing
vaccines. Regarding the HB vaccine, it was shown that the
vaccine was safe and that the risk of T1D did not differ
between children at birth and those vaccinated later (90). A
study in children with an increased genetic risk for T1D who
received the influenza vaccine during the A/H1N1 2009
pandemic showed that this vaccine was not associated with an
increased risk of islet autoimmunity, multiple islet
autoantibodies or type 1. The hazard ratio [HR] (95% CI) for
the appearance of at least one islet autoantibody was 0.75 (0.55-
1.03), for at least two autoantibodies was 0.85 (0.57-1.26) and for
T1D was 0.67 (0.42-1.07) (90). Regarding the HPV vaccine, no
risk of T1D was found after HPV vaccine administration in two
French studies (OR 1.2; 95% CI 0.4-3.6 in the first and HR 1.07;
95% CI 0.87-1.31 in the second) (91, 92). Similar results were
reported in a retrospective cohort study carried out in the USA in
which no increased risk of T1D associated with the HPV vaccine
was found over the 10 years of the study period when comparing
vaccinated with unvaccinated subjects (HR 1.21; 95% CI 0.94-
1.57) (93). Moreover, autoimmune-specific safety analyses
performed separately as part of this larger safety study noted a
decreased association between HPV and new-onset T1D (HR
0.57; 95% CI 0.47-0.73) (94).
All these findings seem to indicate that the vaccines usually
recommended for child protection are safe and not associated
with the risk of T1D development, though it was not
definitively established whether a certain degree of protectionFrontiers in Immunology | www.frontiersin.org 5might be associated with very early administration of one or
more vaccines. Some doubts may still exist for rotavirus
vaccines. In general, the results of recently performed studies
are conflicting, and a global evaluation of available data does
not allow for firm conclusions, though the populations included
in each database are quite different, as are the assumptions,
inclusion criteria, and methods used for analysis. Moreover, it
cannot be excluded that differences among studies are related to
population variations in genetic background or other factors
found to be associated with an increased risk of T1D
development. Two studies carried out in Finland comparing
the incidence of T1D in children with or without rotavirus
vaccination showed no difference between the groups at short
or long-time frames since immunization. The first study
examined children at 4-6 years of age, and the absolute risk
reduction of T1D development was 0.91 (95% CI 0.69–1.20)
(95). In the second study enrolled children who had received
the vaccine 11-14 years before, and the prevalence of T1D was
similar in both groups, at 0.97% (25 of 2,580 children) in the
control group and 1.04% (33 of 3,184 children) in the vaccine
group (P = 0.810) (96). Conversely, completely different results
have been reported by other studies. In studies carried out in
Australia (97) and in the USA (98), vaccines were found to exert
a protective effect, as the incidence of T1D measured before and
after vaccine introduction decreased by 15% (relative risk [RR]
0.86; 95% CI 0.74-0.99) and 33% (HR 0.67; 95% CI 0.54-0.83),
respectively, in vaccinated children. However, in the USA,
differences between vaccines were attributed to a stronger
effect of the pentavalent vaccine compared to the monovalent
vaccine. Moreover, two very recent studies in which several
sensitivity analyses to reduce the risk of bias were carried out
did not find any influence of rotavirus vaccines on the risk of
T1D (99, 100).CONCLUSIONS
T1D is not a rare disease. Nevertheless, several problems related to
the use of vaccines in children with this disease have not been
completely resolved, making administration of vaccines a challenge.
T1D is considered a risk factor for infection development, and based
on the incidence of infections in adults, mainly those with T2D, it is
presumed that children are also at an increased risk of infection.
However, data in this regard are scant, and the infections that must
be monitored in children have not been established. To reduce the
risk of infection, vaccines are strongly recommended in children
with T1D. However, there are few studies regarding the
immunogenicity and efficacy of vaccines in T1D children, and the
need for different immunization schedules has not been precisely
established. Fortunately, the previous presumed relationship
between vaccine administration and T1D development appears to
have been debunked, though some doubts regarding rotavirus
vaccines remain. Further studies are needed to completely resolve
the problems related to vaccine administration in T1D patients. In
the meantime, the use of vaccines remains extensively
recommended in children with this disease.August 2021 | Volume 12 | Article 667889
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